New therapeutic indications for SGLT2 inhibitors

Czech version

Authors: Zbynek Schroner ^1,2
Authors‘ workplace: SchronerMED s. r. o., Košice ¹; Klinika geriatrie a ošetrovateľstva LF UPJŠ a VŠOÚG sv. Lukáša v Košiciach n. o. ²
Published in: Diab Obez 2022; 22(44): 91-94
Category: Reviews

Overview

At present the main target of complex therapy of type 2 diabetes mellitus is except for glycemic compensation also decrease of global cardiovascular and renal risk. Cardioprotective and renoprotective effect of SGLT2 inhibitors was in recently published studies proven also in non-diabetics. By clinical studies are proven new therapeutic indications for SGLT2 inhibitors and also in Slovakia new enlarged indications limitations for this group of drugs.

Keywords:

SGLT2 inhibitors – heart failure – chronic kidney disease – new therapeutic indications

Sources

1. Forxiga. Súhrn charakteristických vlastností lieku Forxiga (dapagliflozín) 2022. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_sk.pdf>.

2. Jardiance. Súhrn charakteristických vlastností lieku Jardiance (empagliflozín) 2022. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/jardiance-epar-product-information_sk.pdf>.

3. McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejecion fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.

4. Packer M, Anker SD, Butler G et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.

5. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.

6. Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387(12): 1089–1098. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2206286>.

7. Wiviott SD, Raz I, Bonaca P et.al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Eng J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.

8. Hiddo JL, Heerspink H, Bergur V et.al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15):1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

9. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT03594110>.

10. Rozhodnutie MZ SR zo dňa 15.5. 2022: Číslo: S16416–2022-OKCHL-23173. Dostupné z WWW: <https://kategorizacia.mzsr.sk/Lieky/Common/Details/21147>.